NCI Pre-Application Webinar for RFA-CA-19-033: Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors-title-h1

NCI Pre-Application Webinar for RFA-CA-19-033: Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors

News
January 28, 2019

On January 31, 2019 from 1:00 to 2:00 p.m. EST, the National Cancer Institute’s (NCI) Division of Cancer Control and Population Sciences (DCCPS) will host a webinar to discuss the Funding Opportunity Announcement (FOA) RFA-CA-19-033, Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required). This webinar will explain the goals and objectives for the FOA and will also answer attendee questions.

Investigators are encouraged to submit questions in advance. This can be done when registering for the webinar at the link below, or by emailing NCIHDRP@mail.nih.gov. Questions sent via email should be submitted to NCI by January 25th, 2019.

Webinar Presentations will be made by:

Sandra Mitchell, Ph.D., Program Director, Healthcare Delivery Research Program
Danielle Daee, Ph.D., Program Director, Epidemiology and Genomics Research Program
Wendy Nelson, Ph.D., Program Director, Behavioral Research Program
Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director, Epidemiology and Genomics Research Program

To register for the webinar, click here: https://bit.ly/2SPLqLJ

Note: RFA-CA-19-033 is associated with the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act of 2018 that is intended to maximize and accelerate discovery, development, and availability of promising childhood cancer treatments. It is also associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. This is not a Kids First funding opportunity announcement.

Icon Media Inquiries

Get Regular Updates


Stay in the loop with data sharing and Kids First DRC news.

Sign up for updates

For Media Inquiries


Please contact Bobby Moulder, Children’s Hospital of Philadelphia.

Contact Us